Reversal of Human Papillomavirus-Specific T Cell Immune Suppression through TLR Agonist Treatment of Langerhans Cells Exposed to Human Papillomavirus Type 16

Laura M. Fahey, Adam B. Raff, Diane M. Da Silva and W. Martin Kast

J Immunol 2009; 182:2919-2928; doi: 10.4049/jimmunol.0803645

http://www.jimmunol.org/content/182/5/2919

**References**
This article cites 50 articles, 20 of which you can access for free at: http://www.jimmunol.org/content/182/5/2919.full#ref-list-1

**Subscription**
Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription

**Permissions**
Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html

**Email Alerts**
Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts
Reversal of Human Papillomavirus-Specific T Cell Immune Suppression through TLR Agonist Treatment of Langerhans Cells Exposed to Human Papillomavirus Type 16

Laura M. Fahey,* Adam B. Rafi,† Diane M. Da Silva,‡§ and W. Martin Kast2*‡§

Human papillomavirus (HPV) type 16 infects the epithelial layer of cervical mucosa and is causally associated with the generation of cervical cancer. Langerhans cells (LC) are the resident APCs at the site of infection and therefore are responsible for initiating an immune response against HPV16. On the contrary, LC exposed to HPV16 do not induce a specific T cell immune response, which leads to the immune evasion of HPV16. Demonstrating that TLR7 and TLR8 are expressed on human LC, we hypothesized that imidazoquinolines would activate LC exposed to HPV16, leading to the induction of an HPV16-specific cell-mediated immune response. Surprisingly, both phenotypic and functional hallmarks of activation are not observed when LC are exposed to HPV16 virus-like particles and treated with imiquimod (TLR7 agonist). However, we found that LC are activated by 3M-002 (TLR8 agonist) and resiquimod (TLR8/7 agonist). LC exposed to HPV16 virus-like particles and subsequently treated with 3M-002 or resiquimod highly up-regulate surface activation markers, secrete proinflammatory cytokines and chemokines, induce CCL21-directed migration, and initiate an HPV16-specific CD8+ T cell response. These data strongly indicate that 3M-002 and resiquimod are promising therapeutics for treatment of HPV infections and HPV-induced cervical lesions. The Journal of Immunology, 2009, 182: 2919–2928.

High-risk human papillomaviruses (HPV)3 are causally linked to the generation of cervical cancer (1, 2). Cervical cancer is the second most common cancer among women worldwide, killing approximately one-quarter of a million women each year (3). Merck has developed the first prophylactic HPV vaccine, Gardasil. It has been demonstrated in phase III clinical trials to be 100% effective in preventing high-grade cervical lesions associated with HPV16 and HPV18 (4, 5). Despite the success of Gardasil, it has been predicted that it will take decades to detect a quantifiable effect on cervical cancer rates in the population (6, 7). Additionally, Gardasil will not aid in treating the hundreds of millions of women that are currently infected with high-risk HPV. The majority of women infected with HPV clear the virus; however, the average time for clearance is close to 1 year (8, 9). Conversely, ~15% of women that have high-risk HPV infections cannot initiate an effective immune response against HPV and persistence of high-risk HPV infection is a major risk factor in the development of cervical cancer (10, 11). The slow clearance rate and lack of an effective immune response indicates that HPV is escaping immune detection (12). Thus, therapeutic treatments are necessary to treat existing high-risk HPV infections.

As we demonstrate here, LC express TLR7 and TLR8; thus, a potential therapy of HPV16-induced lesions would be to activate HPV16-infected LC using synthetic imidazoquinolines (imiquimod, resiquimod, 3M-002, and 3M-031). Imidazoquinolines are TLR7 and/or TLR8 agonists and therefore are potent innate immune modulators (Table I and Ref. 21). TLR7 and TLR8 are localized to endosomal membranes and naturally recognize ssRNA (21, 22). Once TLR7 and/or TLR8 are engaged, NF-κB and other transcription factors are activated, leading to the transcription of immune response-related genes, including cytokine, chemokine, costimulatory marker, and adhesion molecule genes (21, 23, 24). Moreover, imidazoquinolines demonstrate antiviral and antitumor activity through cytokines and chemokines, such as TNF-α, IL-6, IL-8, IL-12, and IFN-inducible...
protein 10 (IP-10), produced by dendritic cells (DC) and macrophages (21, 25–29).

Confirming that TLR7 and TLR8 are expressed on LC, we hypothesized that synthetic imidazoquinolines would activate LC previously exposed to HPV16, leading to the induction of an HPV16-specific immune response. Our results indicate that select imidazoquinolines, TLR8 dominant agonists, are promising therapeutic drugs that could potentially be used as a treatment for HPV infections and HPV-induced cervical lesions by inducing an anti-HPV-specific cell-mediated immune response via the activation of HPV-infected LC.

Materials and Methods

Abs and agonists

The Abs recognizing conformational HPV16 L1 epitopes (H16.V5, H16.E70) or linear HPV16 L1 epitopes (Camvir-1, H16.D9, H16.H5) were gifts from N. Christensen (Penn State, Hershey, PA), except Camvir-1, which was purchased from BD Biosciences. Polyclonal serum (DK44214) recognizing HPV16 L2 was a gift from J. Schiller (National Institutes of Health, Bethesda, MD). The Abs to human CD197 (CCR7)-PE, CD1a-PE, CD80-FITC, CD86-FITC, HLA-DR, DQ, DP-FITC, HLA-A, B, C-FITC, isotype controls, biotinylated anti-human IgG, streptavidin-PE, and streptavidin-HRP were purchased from BD Biosciences. The Ab to human CD207 (langerin) was purchased from Immunotech and the anti-human E-cadherin Ab was purchased from Millipore. Anti-human TLR7 and anti-human TLR8-PE were purchased from Abcam. Goat anti-rabbit-HRP was purchased from BioSource International. Anti-human IFN-γ and biotinylated anti-human IFN-γ Abs were purchased from Mabtech. TLR7, 8, and 7/8 agonists (3M-006, 3M-002, 3M-005, 3M-007, 3M-031) were gifts from 3M Pharmaceuticals.

Donor material

PBL were obtained by leukapheresis from healthy donors. Leukocytes were purified using Lymphocyte Separation Media (Mediatech) by gradient centrifugation, cryopreserved, and stored in liquid nitrogen. HPV serology analysis of all donors showed negative results. All studies using human samples were approved by the University of Southern California’s Institutional Review Board and informed consent was obtained from all donors.

DC and LC generation

Frozen PBL were thawed and washed once with RPMI 1640 containing 2 mM glutamax (Life Technologies), 10 mM sodium pyruvate (Life Technologies), 10 mM nonessential amino acids (Life Technologies), 100 μg/ml kanamycin (Sigma-Aldrich), and 10% FBS (complete medium; Omega Scientific). For DC, plastic adherent cells were selected by plating cells and purified by sucrose and cesium chloride ultracentrifugation as previously described (30, 31). Western blot analysis confirmed the presence of L1, L2, and, in the case of chimeric particles, the E7 protein. To test for intact particles, VLP were subjected to an ELISA using Abs that recognize conformationally dependent L1 surface epitopes or linear epitopes, and transmission electron microscopy. An E-toxate kit (Sigma-Aldrich) was used to quantitate endotoxin and levels in the preparations were found to be 1 < < 0.06 endotoxin units/ml. This level as well as baculovirus DNA used in the VLP production procedure do not activate APC (18).

Imidazoquinoline activation assay

DC and LC were harvested and washed twice with PBS. DC were left untreated or treated with 30 μM 3M-006, 5 μM 3M-002, 30 μM imiquimod, 30 μM resiquimod, 5 μM 3M-031, or with 10 μg LPS (Escherichia coli 026.B6; Sigma-Aldrich). The cells were incubated for 1 h at 37°C, mixed occasionally, and finally placed at 37°C for 24 h in complete medium containing 1000 U/ml rGM-CSF. LC were left untreated or exposed to HPV16 VLP at a concentration of 10 μg/10^9 cells. The cells were incubated for 1 h at 37°C, mixed occasionally, and placed at 37°C for 24 h in complete medium containing 1000 U/ml rGM-CSF. Next, the cells were left untreated or treated with 30 μM 3M-006, 5 μM 3M-002, 30 μM imiquimod, 30 μM resiquimod, 5 μM 3M-031, or 10 μg of LPS and incubated for an additional 24 h at 37°C. DC and LC were harvested, washed, and analyzed by flow cytometry for the expression and surface markers. Additionally, untreated LC and LC exposed to HPV16 VLP were also analyzed for the expression of TLR7 and TLR8.

Cytokine and chemokine analysis

Supernatants were collected from LC stimulated in the imidazoquinolines activation assay and submitted to the Beckman Center for Immune Monitoring Core at the University of Southern California for cytokine and chemokine analysis. The assays were completed using Human Cytokine LINCOplex Kits (LINCO Research) and the Bio-Plex Suspension Array System (Bio-Rad).

Migration assay

Chemoattractant-directed migration of LC was conducted using 24-well Transwell plates with 5-μm pore size polycarbonate filters (Corning Costar). Briefly, 600 μl of medium was added to the lower chamber containing either 250 ng/ml CCL21 (R&D Systems) or complete medium alone, as a control for spontaneous migration. We added 2 × 10^5 untreated LC, LPS-stimulated LC, HPV16 VLP-exposed LC, or HPV16 VLP-exposed LC treated with each of the imidazoquinolines, using the same concentrations as stated in the imidazoquinolines activation assay, to the upper chambers. The plates were incubated for 3 h at 37°C. Cells that migrated to the lower chamber were counted, and migration was calculated as the ratio of cells that migrated with/without CCL21.

In vitro immunization assay

In vitro immunizations assays were performed as described previously (18, 32). Briefly, LC were left untreated or exposed to 10 μg of HPV16 cVLP for 1 h at 37°C in PBS. Subsequently, the cells were incubated for 4 h in complete medium supplemented with 1000 U/ml rGM-CSF at 37°C. Then cells were treated with or without each of the imidazoquinolines and incubated for 20 h at 37°C. As a control for epitope presentation, imidazoquinoline-treated LC were pulsed with a HLA-A2-restricted HPV16-E7 peptide (aa 86–93) (33). LC were irradiated (25 Gy) and mixed with autologous CD8+ T cells isolated from PBL by positive selection using a MACS MultiSort CD8+ isolation kit (Miltenyi Biotec). Day 7 and 14 re-stimulations were done with LC treated as indicated above. For this, the medium was supplemented with IL-2 at 2 × 104 U/ml at 48 and 96 h after restimulation. After 28 days, cells were pooled and tested for IFN-γ production by ELISPOT as a measurement of HPV16-E7-specific CD8+ T cell responses. Briefly, 96-well multiscreen hemagglutination plates (Millipore) were coated with 10 μg/ml anti-human IFN-γ in PBS overnight, washed with PBS/0.5% Tween 20, and blocked for 4 h with complete medium at 37°C/5%CO2. Then, 2.5 × 10^5 cells/well were incubated in the presence or absence of HPV16-E7 peptide aa 86–93 for 18 h at 37°C. The wells were washed six times with PBS/0.5% Tween 20 and plates were incubated for 1 h with streptavidin-HRP conjugate diluted in PBS/0.5% BSA solution. Individual spots were counted after staining with 3-amino-9-ethyl-carbazole substrate (Sigma-Aldrich). Spots were counted using the video-imaging KS ELISPOT analysis system (Zeiss).

Statistical analysis

All statistical analyses were performed using GraphPad Prism. Statistical analyses of the DC activation assay and ELISPOT assay were conducted

<table>
<thead>
<tr>
<th>Imidazoquinoline</th>
<th>Agonist (Receptor(s))</th>
</tr>
</thead>
<tbody>
<tr>
<td>3M-006</td>
<td>Inactive analog (TLR7/8)</td>
</tr>
<tr>
<td>3M-002</td>
<td>TLR8</td>
</tr>
<tr>
<td>Imiquimod</td>
<td>TLR7</td>
</tr>
<tr>
<td>Resiquimod</td>
<td>TLR8/7</td>
</tr>
<tr>
<td>3M-031</td>
<td>TLR7/8</td>
</tr>
</tbody>
</table>

Table I. Synthetic imidazoquinolines and the respective receptor(s) they bind and act through
using a two-tailed t test, as compared with the negative control. Statistical significance of the LC activation assay, cytokine and chemokine analysis, and migration assay were determined by a one-way ANOVA and Tukey’s multiple comparison test as compared with the negative controls.

Results
Characterization of LC

In this study, we are examining TLR7 and/or TLR8 agonists as a means to initiate the activation of HPV16-infected LC, thereby inducing an effective cell-mediated immune response against HPV16. To verify the purity of the LC used in this study, we assessed by flow cytometry the presence of surface markers commonly used to identify LC: langerin, CD1a, and E-cadherin. Our results show that LC generated from human monocytes are a pure population and express LC-associated surface markers; therefore, they are phenotypically equivalent to LC found in the epidermis (Fig. 1A). We also analyzed the expression of both TLR7 and TLR8 in immature LC and HPV16 VLP-exposed LC by flow cytometry. Our results clearly demonstrate that TLR7 and TLR8 are expressed at similar levels in immature LC and LC exposed to HPV16 VLP (Fig. 1B).

3M-002 and resiquimod up-regulate surface markers, MHC class I, MHC class II, CD80, and CD86, on LC that have previously encountered HPV16 VLP and have been treated with each of the imidazoquinolines. DC, which are highly potent professional APC that reside within the dermis, were used as a positive control test for the activity and to determine the optimal concentration of each imidazoquinoline because it has been well established that DC are activated by imidazoquinoline compounds (26, 34, 35). As expected, DC treated with 3M-002, imiquimod, resiquimod, and 3M-031 induced the up-regulation of surface markers, most notably MHC class II and CD86, relative to untreated or 3M-006-treated DC (Fig. 2A). 3M-006 is an inactive small molecule TLR7/8 analog that is produced in a similar manner as the other imidazoquinolines and used as a negative control. The optimal concentration for each imidazoquinoline to activate APC was determined by assessing a range of concentrations (0.1–60 μM) for each agonist. The concentration of each agonist that resulted in the maximum expression of surface markers on DC, as determined by flow cytometry analysis, was used as the optimal concentration (data not shown).

Since we confirmed that the agonists are active and knowing the optimal concentrations needed to activate APC, we investigated whether each agonist has the ability to reverse the phenotype of LC exposed to HPV16 VLP. We assessed phenotypic activation by the expression of surface markers, MHC class I, MHC class II, CD80, and CD86, on LC that have previously encountered HPV16 VLP and have been treated with each of the imidazoquinolines. DC, which are highly potent professional APC that reside within the dermis, were used as a positive control test for the activity and to determine the optimal concentration of each imidazoquinoline because it has been well established that DC are activated by imidazoquinoline compounds (26, 34, 35). As expected, DC treated with 3M-002, imiquimod, resiquimod, and 3M-031 induced the up-regulation of surface markers, most notably MHC class II and CD86, relative to untreated or 3M-006-treated DC (Fig. 2A). 3M-006 is an inactive small molecule TLR7/8 analog that is produced in a similar manner as the other imidazoquinolines and used as a negative control. The optimal concentration for each imidazoquinoline to activate APC was determined by assessing a range of concentrations (0.1–60 μM) for each agonist. The concentration of each agonist that resulted in the maximum expression of surface markers on DC, as determined by flow cytometry analysis, was used as the optimal concentration (data not shown).
with each of the imidazoquinolines. Each population of cells was harvested after the final incubation and analyzed by flow cytometry for the expression of surface markers. Consistent with our previously reported data (18), LC exposed to HPV16 VLP did not increase the expression of surface markers when compared with untreated LC and 3M-006-treated LC (Fig. 2B). LC treated with either 3M-002 or resiquimod significantly induced the up-regulation of surface markers on LC and LC exposed to HPV16 VLP. These data are represented by fold increase in surface marker expression, which are based on mean fluorescence intensity. The mean ± SEM of four separate experiments is presented (*, p < 0.05; **, p < 0.01; and ***, p < 0.001).

**DIFFERENTIAL PRODUCTION OF CYTOKINES AND CHEMOKINES FROM LC STIMULATED WITH IMIDAZOQUINOLINES**

Imidazoquinolines stimulate both an innate and an adaptive immune response. The innate immune response induced by imidazoquinolines drives the adaptive immune response into a Th1 cell-mediated response via the local cytokine and chemokine milieu generated primarily by activated macrophages and DC. Thus, we increased the expression of surface markers on LC exposed to HPV16 VLP, relative to the negative controls (Fig. 2B). Of note, it appears that TLR7 and TLR8 agonists induced a slightly greater up-regulation of surface markers on LC that have previously been exposed to HPV16 VLP than on untreated LC; however, these differences in expression are not statistically significant. Thus, these phenotypic data begin to suggest that imidazoquinolines have different effects on DC and LC. Specifically, 3M-002 and resiquimod appear to be far more potent agonists for LC than imiquimod and 3M-031.
wanted to determine whether selected imidazoquinolines could stimulate LC exposed to HPV16 VLP to produce a proinflammatory cytokine and chemokine profile similar to the cytokine milieu known to be generated by imidazoquinoline-activated DC. Cytokines and chemokines produced by untreated LC, LC exposed to HPV16 VLP, LC treated with each of the imidazoquinolines, or LC exposed to HPV16 VLP and then treated with imidazoquinolines were analyzed in triplicate for the presence of cytokines and chemokines. Cytokine and chemokine levels were quantified using a human cytokine LINCOplex assay. These data are expressed as the mean concentration with error bars representing the SD (*, p < 0.05 and **, p < 0.001). The experiment was repeated three times and yielded similar results.

FIGURE 3. 3M-002 and resiquimod highly induce the secretion of Th1-associated cytokines and chemokines by LC previously incubated with or without HPV16 VLP. Supernatants collected from untreated LC, LC exposed to HPV16 VLP, LC treated with each of the imidazoquinolines, or LC exposed to HPV16 VLP and then treated with imidazoquinolines were analyzed in triplicate for the presence of cytokines and chemokines. Cytokine and chemokine concentrations were statistically significantly elevated when LC were stimulated with 3M-002, resiquimod, or when LC were exposed to HPV16 VLP and then stimulated with either 3M-002 or resiquimod in comparison to the negative controls, untreated LC, LC exposed to HPV16 VLP, 3M-006 treated LC, and LC exposed to HPV16 VLP and treated with 3M-006 (Fig. 3). LC treated with 3M-031 or LC exposed to HPV16 VLP and subsequently stimulated with 3M-031 only slightly induced the production of these cytokines and chemokines above that of the negative controls (Fig. 3). IP-10, MCP-1, and RANTES (CCL5) were also found to be highly secreted by LC treated with 3M-002, resiquimod, or 3M-031 and LC exposed to HPV16 VLP and then stimulated with
either 3M-002, resiquimod, or 3M-031 (data not shown). Markedly, imiquimod-stimulated LC and LC exposed to HPV16 VLP and subsequently treated with each of the imidazoquinolines. After the final incubation, LC were either: A, harvested and analyzed for the expression of CCR7 (black line) by flow cytometry (gray line is the isotype control Ab) or B, used in a migration assay. The mean ± SEM of three separate experiments is presented (***, p < 0.001).

**FIGURE 4.** 3M-002 and resiquimod induce the up-regulation of CCR7 and migration of LC exposed to HPV16 VLP toward CCL21. LC were left untreated, stimulated by LPS, exposed to HPV16 VLP, or exposed to HPV16 VLP and subsequently treated with each of the imidazoquinolines. Untreated LC, LPS-stimulated LC, LC exposed to HPV16 VLP, and LC exposed to HPV16 VLP and subsequently treated with each of the imidazoquinolines were analyzed for the expression of CCR7 by flow cytometry. LC exposed to HPV16 VLP stimulated with either 3M-002 or resiquimod induced the up-regulation of CCR7 similar to the positive control LPS-treated LC (Fig. 4A). In contrast, imiquimod and 3M-031 did not induce the expression of CCR7 on LC previously exposed to HPV16 VLP (Fig. 4A). Next, we examined whether the expression of CCR7 functionally corresponded to enhanced migration of LC toward CCL21 by a Transwell migration assay. **B**, Migration Index. The mean ± SEM of three separate experiments is presented (***, p < 0.001).

3M-002 and resiquimod induce the up-regulation of CCR7 and migration of LC exposed to HPV16 VLP toward CCL21.

In addition to the up-regulation of surface markers and the secretion of proinflammatory cytokines and chemokines, another hallmark of LC activation is the up-regulation of CCR7 and the migration out of peripheral tissues toward draining LN. CCR7 mediates the migration of LC to T cell zones of the draining LN by binding to either secondary lymphoid tissue chemokine (secondary lymphoid tissue chemokine/CCL21) or MIP-3β (CCL19). Therefore, we investigated whether the imidazoquinoline compounds can induce the up-regulation of CCR7 and CCL21-directed migration of LC exposed to HPV16 VLP. Untreated LC, LPS-stimulated LC, LC exposed to HPV16 VLP, and LC exposed to HPV16 VLP and subsequently treated with each of the imidazoquinolines were analyzed for the expression of CCR7 by flow cytometry. LC exposed to HPV16 VLP stimulated with either 3M-002 or resiquimod induced the up-regulation of CCR7 similar to the positive control LPS-treated LC (Fig. 4A). In contrast, imiquimod and 3M-031 did not induce the expression of CCR7 on LC previously exposed to HPV16 VLP (Fig. 4A). Next, we examined whether the expression of CCR7 functionally corresponded to enhanced migration of LC toward CCL21 by a Transwell migration assay.
assay. We observed that 3M-002 and resiquimod significantly induced the migration of LC exposed to HPV16 VLP toward CCL21, as seen similarly in the positive control, while imiquimod and 3M-031 did not enhance CCL21-directed migration of LC exposed to HPV16 VLP (Fig. 4b). Taken together, these experiments demonstrate that 3M-002 and resiquimod are providing LC exposed to HPV16 VLP with a potent stimulus to acquire the potential to migrate effectively in response toward a LN-derived chemokine, CCL21.

**Induction of an epitope-specific CD8+ T cell response by LC exposed to HPV16 cVLP and stimulated with either 3M-002 or resiquimod**

Thus far, we have demonstrated that 3M-002 and resiquimod can effectively activate LC previously exposed to HPV16 VLP, unlike imiquimod and 3M-031; therefore, we next sought to determine whether LC exposed to HPV16 VLP and stimulated with each of the imidazoquinolines could induce an HPV16-specific, MHC class I-restricted T cell response by performing in vitro immunization assays. HPV16 cVLP were used in these experiments because they contain a well-characterized human HLA-A*0201-restricted epitope (E7 peptide aa 86–93, TLGIVCPI) recognized by human CD8+ T cells (33). Human DC, but not LC, have been shown to initiate epitope-specific responses to this peptide when exposed to the HPV16 cVLP (18, 32). Thus, HPV16 cVLP were used to determine whether the imidazoquinoline compounds are capable of stimulating LC exposed to HPV16 VLP to initiate an epitope-specific immune response against the HPV16 E786–93 peptide.

In the experiments presented here, LC generated from HLA-A*0201-positive monocytes were exposed to HPV16 cVLP and treated with each of the imidazoquinolines. We then incubated the cells with autologous naive CD8+ T cells and the cultures were stimulated twice with their respective treated LC. As control treatments, LC were treated with each of the imidazoquinolines and pulsed with the HPV16-E7-derived HLA-A*0201-restricted CTL epitope (E786–93). Seven days after the last restimulation, the cells from each culture were collected and analyzed for a specific CD8+ T cell response to the HLA-A*0201-restricted HPV16-E786–93 peptide by an IFN-γ ELISPOT. Of major impact, LC exposed to HPV16 cVLP and stimulated with either 3M-002 or resiquimod initiated a statistically significant HPV16 epitope-specific response when compared with untreated LC and LC exposed to HPV16 cVLP, while LC exposed to HPV16 cVLP and stimulated with either imiquimod or 3M-031 did not induce a significant HPV16 epitope-specific immune response (Fig. 5). Collectively, these experiments demonstrate that both 3M-002 and resiquimod effectively induce LC activation and have the ability to initiate an HPV16-specific cell-mediated immune response through the activation of LC.

**Discussion**

In this study, we investigated synthetic imidazoquinolines as potential activators of LC previously exposed to HPV16 VLP, which could lead to further exploration of specific imidazoquinolines as therapeutic compounds for treating existing HPV16-induced cervical lesions. Our data clearly demonstrate that 3M-002 and resiquimod can induce the phenotypic maturation of naive LC and LC previously exposed to HPV16 VLP via the up-regulation of surface markers (MHC class I, MHC class II, CD80, and CD86). Moreover, 3M-002 and resiquimod induce functional activation of LC exposed to HPV16 VLP as demonstrated by the production of Th1-associated cytokines and chemokines, CCL21-directed migration, and the induction of an HPV16-specific CD8+ T cell response. However, imiquimod does not phenotypically or functionally activate LC while 3M-031 partially induces the activation of LC. Collectively, our data strongly suggest that 3M-002 and resiquimod can reverse the phenotype and function of LC exposed to HPV16, unlike imiquimod and 3M-031. Therefore, our results support exploring 3M-002 and resiquimod as therapeutic small-molecule compounds for treating HPV infections and HPV-induced cervical lesions.

The findings presented here are based upon a model system that mimics the interaction between HPV and LC in the human epithelium. Due to limitations of working with human material, the study was not conducted using human LC isolated from mucosal epithelial sheets. The mere process of isolating human LC from epidermal sheets induces the maturation of LC (36), thus making it difficult to carry out our study since activation status is an end point. However, monocyte-derived LC are an appropriate alternative model, because they express MHC class II molecules, langerin, E-cadherin, CD1a, and Birbeck granules (18), which classically define human LC located in the epidermis (37). Recently, the status of LC as the only APC in the epithelium that express langerin was challenged. It was reported that dermal langerin+ DC exist in mice and may play a role in the immunosurveillance of the skin (38, 39). However, Klechevsky et al. (36) demonstrated that although two different subsets exist of human dermal DC, neither of these subsets express langerin, highlighting a difference in human and murine APC populations located in the epithelium (36). Moreover, this study was conducted using VLP, which have been developed as an alternative to HPV virions for immunological analysis. This is because the life cycle of HPV is dependent on the differentiation of cells in the squamous epithelium, making it very difficult to produce large quantities of HPV virions in vitro. Thus, due to
the facts that human LC are the only APC at the site of infection, that monocyte-derived LC have been shown to be phenotypically equivalent to human epidermal LC, and that VLP are an accepted alternative to purified virions for immunological analysis of HPV, this study uses the most appropriate model to critically examine the interaction of HPV and human LC.

It should be noted that imiquimod is a Food and Drug Administration-approved drug (Aldara) to treat external anogenital warts (condyloma acuminate) caused by low-risk HPV infection (HPV 6 and 11). More recently, imiquimod has been shown to be successful in treating high-risk HPV-induced vulvar intraepithelial neoplasia (VIN) (40, 41). However, imiquimod has yet to be reported as an effective therapeutic treatment for HPV-induced cervical intraepithelial neoplasia. The reason why there is a difference in response initiated by imiquimod against different types of HPV-induced lesions (genital warts, VIN lesions, and cervical intraepithelial neoplasia lesions) is unclear. This disparity in response could be due to the difference in cellular composition and structure of the external genitalia and the cervix. Considering, we demonstrate that imiquimod does not activate LC, an effective immune response against anogenital warts and VIN lesions is likely due to the activation of APC other than LC, such as DC and macrophages.

The effects of synthetic imidazoquinolines on LC had not been well studied until now. Previously, it was shown that imiquimod and resiquimod do not phenotypically but functionally activate LC (42, 43). Past studies assessed phenotypic activation of LC by the expression of surface markers. The results from these studies are in accordance with our results for imiquimod; however, we found that resiquimod does phenotypically activate LC. The reason for this discrepancy between the present and past studies, concerning the effects of resiquimod on LC, could be explained because Burns et al. (42) examined phenotypic activation 6 h after LC were treated with resiquimod, while we assessed the maturation of LC 24 h after treatment with resiquimod. Furthermore, the functional activation of LC was examined in the previous studies in multiple ways, one of which was by the level of mRNA-encoding proinflammatory cytokines, such as TNF-α, IL-6, and IL-12p40. The results from these studies showed that imiquimod and resiquimod enhanced the transcription of the genes for these specific cytokines. We also assessed cytokine levels as a means of evaluating functional activation; however, we did so at the more relevant level of protein production. We observed proinflammatory cytokine and chemokine secretion by LC treated with either 3M-002 or resiquimod and to a modest extent with 3M-031; however, we did not observe this with imiquimod. Our results are an improvement on previous reports because we assayed for a different end product, namely, protein, and mRNA transcripts do not always translate to protein expression. Additionally, our results are consistent with recent findings showing that TLR8 agonists are more effective than TLR7 agonists at inducing proinflammatory cytokines and chemokines by monocyte-derived DC (GM-CSF/IL-4/TGF-β) (23).

During activation LC migrate out of the epidermal tissue to draining LN where they activate naïve T cells, thereby inducing a cell-mediated immune response. Previous data have demonstrated that LC exposed to HPV16 VLP cannot up-regulate CCR7, migrate, or induce an HPV16-specific CD8+ T cell response (18, 20). To explore the effects of synthetic imidazoquinolines on the migration of LC exposed to HPV16 VLP, we assessed the expression of CCR7 and the ability of LC previously exposed to HPV16 VLP to migrate toward CCL21. Our results clearly show CCR7 is up-regulated on LC exposed to HPV16 VLP that are treated with either 3M-002 or resiquimod, but not when treated with imiquimod or 3M-031. Furthermore, we demonstrate that the expression of CCR7 correlates to the migratory ability of LC exposed to HPV16 VLP. Our data illustrate that only 3M-002- and resiquimod-treated LC previously exposed to HPV16 VLP are able to migrate in response to CCL21. However, in a contrasting study, it was shown that imiquimod functionally activates LC by demonstrating that imiquimod induces the migration of LC, yet the study was performed using a mouse model and it was not confirmed that the migrating LC were effective in inducing an epitope-specific adaptive immune response (43). Nevertheless, we sought to determine whether LC exposed to HPV16 VLP that are treated with imidazoquinolines have the ability to induce an HPV16 epitope-specific CD8+ T cell response. Our results show that 3M-002 and resiquimod can effectively overcome the phenotype and function of LC exposed to HPV16 VLP and can induce an HPV16-specific CD8+ T cells response, which is critical in mediating the clearance of HPV16 infections and HPV16-induced cervical lesions. In addition to our findings, Burns et al. (42) investigated the functional activation of LC after treatment with either imiquimod or resiquimod by assessing the allostimulatory capacity of the treated LC. They found that imiquimod only modestly induced T cell proliferation in an allogenic MLR assay while resiquimod highly increased the allostimulatory capacity of LC (42). Their results from this functional assay are in line with our functional data, which is further support that resiquimod is more potent than imiquimod in activating LC.

Collectively, our findings imply that strong TLR8 agonists, such as 3M-002 and resiquimod, are more effective in inducing LC activation and overcoming the tolerizing-like phenotype and function of LC exposed to HPV16 VLP, in comparison to TLR7 agonists, such as imiquimod. It has been shown that TLR7 and TLR8 agonists differ in their target cell selectivity (23). Notably, resiquimod and 3M-031 are both TLR7 and TLR8 agonists; however, resiquimod is much more effective in activating LC. This may occur because the agonists differ in their target cell selectivity and preferentially activate one TLR over the other; resiquimod is known to preferentially act through TLR8 (21), while it has yet to be reported which receptor 3M-031 preferentially acts through. This explanation is plausible considering that functional differences have been observed between TLR7 and TLR8 (23, 44). It was demonstrated that TLR7 activation primarily leads to the production of IFN-α- and IFN-regulated cytokines, which is similar to TLR9 activation, while TLR8 is functionally associated with the production of proinflammatory cytokines, such as TNF-α (23). One explanation for the functional distinction between TLR7 and TLR8 is the difference in the signal transduction pathways initiated by each of the receptors. TLR8-mediated activation of NF-κB and JNK are dependent on MEK kinase 3 (45), while TLR7-mediated activation of NF-κB is TGF-β-activated kinase 1 dependent (46). Bruton tyrosine kinase has also been shown to directly interact with the intracellular domain of TLR8 and plays an important role in the signal transduction of TLR8, yet Bruton tyrosine kinase has not been demonstrated to be associated with TLR7 (47, 48). Alternatively, another explanation of our findings may be that TLR8 is inhibiting TLR7 function. In HEK293 cells, it was demonstrated that the coexpression of TLR8 and TLR7 results in inhibition of TLR7 to respond to its agonist (44). Therefore, TLR8 may inhibit LC from responding to agonists that preferentially bind TLR7, which explains why TLR8-dominant agonists (such as 3M-002 and resiquimod) are more effective than
TLR7-dominant agonists (such as imiquimod and potentially 3M-003) in activating LC and in driving a strong cell-mediated immune response. Since LC are critical in controlling the induction of an immune response in the epithelium and they are targeted by HPV16 to escape immune detection, LC are highly attractive targets for immunotherapy of HPV16-induced cervical lesions. In addition, LC have recently been shown to be able to directly kill cervical epithelial cells that express HPV16 E6 and E7, thereby generating a source of Ag that could be processed and presented by APC to T cells. LC cytotoxicity is mediated in part by TRAIL expression, which can be up-regulated by the presence of IFN-γ (49). Furthermore, it has been demonstrated that TLR7/8-stimulated DC-like cells have cytotoxic activity, which is mediated by the expression of TRAIL and the secretion of perforin and granzyme B (50). Thus, it is conceivable that TLR8 agonists stimulate LC not only to induce an HPV-specific Th1-mediated cellular immune response but may also enhance LC cytotoxicity toward HPV16-infected epithelial cells, further augmenting antiviral and antineoplastic activity. In conclusion, TLR8 agonists, 3M-002 and resiquimod, are promising therapeutic agents for augmenting antiviral and antineoplastic activity. In conclusion, TLR8 agonists do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses. J. Immunol. 169: 324 –324.


